Among the most fascinating applications of CRISPR in metabolic disorders is editing PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), a basic regulator of cholesterol metabolism. This evidence concerns the gene PCSK9 and Other metabolic disease.